ImmunoPrecise Antibodies Ltd. (IPA)

Market Cap	20.04M
Revenue (ttm)	16.58M
Net Income (ttm)	-32.30M
Shares Out	45.77M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251,874
Open	0.4300
Previous Close	0.4270
Day's Range	0.4270 - 0.4330
52-Week Range	0.2700 - 1.3900
Beta	0.38
Analysts	Strong Buy
Price Target	4.00 (+823.79%)
Earnings Date	Mar 28, 2025

About IPA

ImmunoPrecise Antibodies Ltd., a techbio company, engages in the development of therapeutic antibodies. It leverages multi-omics modeling and artificial intelligence through a series of proprietary and patented technologies. The company’s contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based on building custom immune librari...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: IPA
• Website: https://www.ipatherapeutics.com

Financial Performance

In 2024, ImmunoPrecise Antibodies's revenue was 24.52 million, an increase of 18.65% compared to the previous year's 20.67 million. Losses were -27.18 million, 2.32% more than in 2023.

Financial numbers in CAD

Analyst Forecast

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 823.79% from the latest price.

Price Target

$4.0

(823.79% upside)

Analyst Consensus: Strong Buy